Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
grade D 1.18 -1.67% -0.02
SCYX closed down 1.67 percent on Wednesday, November 13, 2019, on approximately normal volume.

Earnings due: Dec 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical SCYX trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
200 DMA Resistance Bearish -1.67%
50 DMA Support Bullish -1.67%
Crossed Above 20 DMA Bullish -1.67%
Volume Surge Other -1.67%
Wide Range Bar Range Expansion -1.67%
Fell Below 20 DMA Bearish 3.51%
MACD Bearish Signal Line Cross Bearish 3.51%
50 DMA Support Bullish 3.51%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.51%

Older signals for SCYX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Medicine Medical Specialties Pharmaceutical Drugs Medication Anti Infectives Hepatitis C Interferon Pegylation Dry Eye Disease
Is SCYX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.9
52 Week Low 0.35
Average Volume 331,836
200-Day Moving Average 1.2749
50-Day Moving Average 1.1178
20-Day Moving Average 1.1655
10-Day Moving Average 1.218
Average True Range 0.0889
ADX 23.69
+DI 24.1316
-DI 14.3776
Chandelier Exit (Long, 3 ATRs ) 1.1733
Chandelier Exit (Short, 3 ATRs ) 1.3067
Upper Bollinger Band 1.3066
Lower Bollinger Band 1.0244
Percent B (%b) 0.55
BandWidth 24.212784
MACD Line 0.0275
MACD Signal Line 0.0303
MACD Histogram -0.0028
Fundamentals Value
Market Cap 31.53 Million
Num Shares 26.7 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -1.23
Price-to-Sales 193.40
Price-to-Book 1.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.30
Resistance 3 (R3) 1.31 1.29 1.28
Resistance 2 (R2) 1.29 1.26 1.28 1.27
Resistance 1 (R1) 1.23 1.24 1.22 1.22 1.27
Pivot Point 1.21 1.21 1.20 1.20 1.21
Support 1 (S1) 1.15 1.18 1.14 1.14 1.09
Support 2 (S2) 1.13 1.16 1.12 1.09
Support 3 (S3) 1.07 1.13 1.08
Support 4 (S4) 1.06